

27. (Once Amended) A composition comprising

G¹
(a) a fatty acid-acylated insulin or a fatty acid-acylated insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted, and

(b) zinc.

28. (Once Amended) A composition comprising an aqueous solution of

G²
(a) a fatty acid-acylated insulin or a fatty acid-acylated insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted, and

(b) zinc.

G³
29. (Once Amended) The composition of Claim 28, wherein the solution comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin or fatty acid-acylated insulin analog.

G⁴
32. (Once Amended) The composition of Claim 31, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin, and wherein the fatty acid-acylated insulin analog is an N-acylated Lys^{B29} insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted.

G⁵
58. (Once Amended) The composition of claim 27, wherein the composition comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin or fatty acid-acylated insulin analog.

G⁶
60. (Once Amended) The composition of Claim 27, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin, and wherein the fatty acid-acylated insulin analog is an N-acylated Lys^{B29} insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted.

BEST AVAILABLE COPY

G¹
61. (Once Amended) The composition of claim 32, wherein the fatty acid-acylated insulin is N-myristoyl Lys^{B29} human insulin, and wherein the solution comprises from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

G⁸
64. (Once Amended) The composition of claim 63, wherein the phenolic compound is selected from the group consisting of phenol and m-cresol.

Add new claims 65-67.

--65. (New) The composition of Claim 27, wherein the fatty acid in the fatty acid-acylated analog is myristic acid.

G⁹
66. (New) The composition of Claim 28, wherein the fatty acid in the fatty acid-acylated analog is myristic acid.

67. (New) The composition of claim 58, wherein the pH is 6.8 to 7.8.--

Remarks

I. Documents Filed Herewith

Filed herewith are:

- (a) A Request for Continued Examination (RCE);
- (b) An information disclosure statement;
- (c) A Request for Interference under 37 C.F.R. § 1.607;
- (d) 5 declarations and 16 documentary exhibits which constitute evidence demonstrating that Applicants are *prima facie* entitled to a judgment relative to effective filing date of U.S. patent no. 5,750,497 ("the '497 patent") and U.S. patent no. 6,011,007 ("the '007 patent"); and
- (e) An explanation under 37 C.F.R. § 1.608(b) of the evidence stating with particularity the basis upon which

BEST AVAILABLE COPY